Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 28 | SFEBES2012 | Next issue

Society for Endocrinology BES 2012

Oral Communications

Growth, tumours and pituitary

ea0028oc5.1 | Growth, tumours and pituitary | SFEBES2012

Human growth is regulated by an ubiquitination pathway including CUL7, OBSL1 and CCDC8

Hanson Dan , Murray Philip , Coulson Tessa , Saunders Emma , Omokanye Ajibola , Carter Emily , Sud Amit , Whatmore Andrew , Black Graeme , Clayton Peter

3-M syndrome is characterised by post-natal growth restriction. We have identified causative mutations in three genes CUL7, OBSL1 and CCDC8. CUL7, a component of an E3 ubiquitin ligase, has a binding domain for p53 and its reduction or absence has a major impact on growth and cell division. OBSL1 is postulated to have a role as a cytoskeletal adaptor, and was not recognised previously to be a growth regulator. The domain structure of CCDC8 predicts a possi...

ea0028oc5.2 | Growth, tumours and pituitary | SFEBES2012

A network analysis of gene expression through childhood highlights changes related to age and growth

Stevens Adam , Whatmore Andrew , Clayton Peter

Objective: To assess age- and growth-dependent gene expression in children and correlate this with biological pathways.Methods: We conducted a gene expression meta-analysis on datasets from normal children curated from the NCBI Gene Expression Omnibus (GEO). Four datasets were combined to form a group of 87 individuals ranging from 0.2 to 29.3 years of age (average 7.7±6.9yr). Analysis of gene expression data was performed using hierarchical cluster...

ea0028oc5.3 | Growth, tumours and pituitary | SFEBES2012

Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?

Sze Wing-Chiu , Murray Iain , Avril Norbert , Drake William , Akker Scott , Grossman Ashley , Plowman Nick , Druce Maralyn

Introduction: 131I-MIBG is a well-established treatment modality for patients with neuroendocrine tumours (NETs). Our centre has now accumulated over 10 years of experience with 131I-MIBG therapy, with long term data to evaluate effects on disease progress and other long term outcomes following therapy. Bone marrow effects of radionuclide therapy may include prolonged suppression, myelodysplasia or even frank leukaemia. Incidence is thought to be low, but...

ea0028oc5.4 | Growth, tumours and pituitary | SFEBES2012

Steroid metabolomics in adrenocortical carcinoma reveals mitotane as an inducer of CYP3A4 and an inhibitor of 5alpha-reductase activity with major implications for drug metabolism and hydrocortisone replacement

Chortis Vasileios , Taylor Angela , Schneider Petra , Tomlinson Jeremy , Hughes Beverly , Smith David , Porfiri Emilio , Shackleton Cedric , Stewart Paul , Arlt Wiebke

Mitotane (o,p’DDD) is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumour. Mitotane is considered an adrenolytic substance, but no information is available regarding distinct steroidogenic effects. Here we carried out steroid metabolomics by gas chromatography/mass spectrometry in 24-hour urine samples from 106 patients with ACC and with samples coll...

ea0028oc5.5 | Growth, tumours and pituitary | SFEBES2012

Role of the hypoxic signalling pathways in the histopathological prediction of malignancy in phaeochromocytomas and paragangliomas

Pinato David , Ramachandran Radha , Toloue Kalami Toussi Samin , Vergine Marco , Ngo Nyethane , Sharma Rohini , Khoo Bernard , Meeran Karim , Palazzo Fausto , Martin Niamh , Dina Roberto , Tan Tricia

Backgeound and Aims: Phaeochromocytomas (PCC) and paragangliomas (PGL) are mostly benign sympathoadrenal tumours. However, there are no available markers to predict a malignant course. Since hypoxia is involved in the pathogenesis of these tumours, we aimed to qualify the relevance of the mammalian Target of Rapamycin (m-TOR) and hypoxic pathways in benign and malignant PCC/PGL.Methods: Tissue microarray (TMA) blocks were constructed with 80 PCC/PGL, inc...

ea0028oc5.6 | Growth, tumours and pituitary | SFEBES2012

SUMOylation genes in pituitary gonadotrophs: wrestling with GnRH signalling

Mirczuk Samantha , Wilkinson Samantha , Savage Alyssa , Sunters Andrew , Simbi Bigboy , McArdle Craig , Lee Martin , Fowkes Robert

The orphan nuclear receptor, SF-1, is sumoylated in adrenal and gonadal tissues, but the role of sumoylation in pituitary gonadotrophs is currently unknown. We performed expression studies for key components of sumoylation machinery in αT3-1 and LβT2 gonadotroph cell lines, using RT-PCR. Expression of the genes encoding the SUMO proteins (Sumo1, Sumo2, Sumo3) as well as the E3 ligase enzymes responsible for their covalent linkage (Pias1, Pias2/xα, Pias...

ea0028oc5.7 | Growth, tumours and pituitary | SFEBES2012

The role of the familial pituitary adenoma gene, AIP, in the proliferative and invasive activity of a malignant pancreatic cell line

Saleh Jumana , Barry Sayka , Korbonits Marta

Background: Heterozygote mutations in the aryl hydrocarbon receptor-interacting protein (AIP) predispose carriers to young-onset pituitary adenomas, most often somatotroph or lactotroph adenomas. No other tumour type has been consistently detected in AIP mutation positive families, despite the fact that AIP is ubiquitously expressed. Current clinical and experimental data suggest that AIP is a tumour suppressor gene.Aims: To investigate the tumour suppre...

ea0028oc5.8 | Growth, tumours and pituitary | SFEBES2012

Control of GH and IGF1 in acromegaly in the UK: Responses to medical treatment

Howlett Trevor , Willis Debbie , Walker Gillian , Wass John AH , Trainer Peter , UK National Acromegaly Register Investigators

UK National Acromegaly Register collects data on routine clinical practice in 34 centres. We analysed all GH and IGF1 data to assess adequacy of control & responses to medical treatment (Rx) with somatostatin analogs (SMS) & dopamine agonists (DA). Methods: Under program control, GH records (basal, profile or GTT) were correlated with IGF1, tumour size, Rx, surgery (TSS) & radiotherapy (RT) in the database, then processed in Excel to derive summary data for each pa...